NeoGenomics: Navigating the Ever-Changing Biomarker & CDx Landscapes to Ensure Stakeholder Alignment & Wide-Spread Accessibility
Time: 5:50 pm
day: Day 1 PM
Details:
• Tumor informed MRD can support clinical development in a number of ways (e.g. patient enrichment, monitoring, surveillance)
• While many MRD applications for solid tumors continue to emerge, CDx development with these technologies will also be required in the near future
• NeoGenomics is uniquely positioned with the RaDaR technology to support all MRD applications for drug development, including CDx development through commercialization
